Health — 12 August 2013

By Pat Anson, Editor

Multiple sclerosis patients who use an oral cannabinoid spray showed no long-term cognitive impairment or changes in mood, according to a new study released by GW Pharamaceuticals, a British biopharmaceutical company.

The spray, sold under the brand name Sativex, is approved for use in Europe, Canada and Mexico to treat multiple sclerosis (MS) symptoms and cancer pain, but is currently not approved for sale in the United States. GW Pharmaceuticals hopes to see FDA approval by the end of 2013.

“We are pleased to report positive and wholly reassuring results from this 12 month placebo-controlled study in patients with MS spasticity,” said Dr. Stephen Wright, GW Pharmaceuticals research and development director.

“We have now shown that Sativex does not impair cognition either in short-term or in long-term use in well designed, randomized, placebo controlled clinical trials.  These data not only confirm the good tolerability of Sativex in long-term use but also provide further evidence of efficacy consistent with that seen in previous shorter duration clinical trials.”

Read more at National Pain Report.


About Author

Pat Anson, Editor

Pat is Editor in Chief of American News Report. He is a veteran journalist and a former correspondent and producer for HealthWeek (PBS), Nightly Business Report (PBS) and other nationally syndicated shows. Pat has won numerous journalism awards, including a Golden Mike award for investigative reporting.

(0) Readers Comments

Comments are closed.